Blogs
From the Proscia blog: Every patient’s care journey starts with a diagnosis. As our understanding of disease becomes more nuanced, pathologists are expected to deliver increasingly specific answers. Meanwhile, their expertise is in short...
From the Proscia blog: Interoperability remains a major barrier to the scaled adoption of digital pathology. Signify Research took this away from their recent discussions with seven pathologists and leaders across academic and health...
From the FormaPath blog: FormaPath was honored to be featured by Mecademic Industrial Robotics, highlighting the integration of the Meca500 robotic arm within the nToto platform. By combining Mecademic's micrometer-level precision robotics...
From the Gestalt blog: Healthcare IT isn’t shrinking, it’s resetting. After the surge of pandemic-era hiring, many health systems are stepping back and asking a hard question: does more headcount actually make us more agile? In 2026,...
From Proscia on LinkedIn When evaluating an enterprise pathology platform, many life sciences organizations and diagnostic laboratories focus on the features it offers. This makes sense since scientists and pathologists will rely on that...
Nucleai, Gilead, and target-positive tumors Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward...
